PRF Technologies (PRFX) Common Equity (2019 - 2025)
PRF Technologies (PRFX) posted quarterly Common Equity of $9.3 million for Q4 2025, up 409.32% year-on-year from $1.8 million in Q4 2024, and up 10.03% on a QoQ basis from $8.4 million in Q2 2025.
PRF Technologies (PRFX) Common Equity (2019 - 2025) Analysis & Trends
PRF Technologies (PRFX) has reported Common Equity for 7 consecutive years, with $9.3 million the latest figure, recorded in Q4 2025.
- Quarterly Common Equity rose 409.32% year-over-year to $9.3 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $9.3 million (up 409.32% YoY) and the FY2025 annual result came in at $9.3 million, up 409.32% from the prior year.
- Common Equity improved to $9.3 million in Q4 2025 per PRFX's latest filing, from $8.4 million in the prior quarter.
- Over the last five years, Common Equity for PRFX reached as high as $20.4 million in Q1 2021 and fell as low as -$2.0 million in Q2 2024.
- A 5-year average of $10.8 million and a median of $9.3 million in 2025 frame the typical range for Common Equity.
- Annual changes were most pronounced in 2024 — Common Equity slumped 129.27% — and 2025, when it soared 513.67%.
- Year by year, Common Equity stood at $18.1 million in 2021, then tumbled by 39.05% to $11.0 million in 2022, then slumped by 34.32% to $7.2 million in 2023, then slumped by 74.8% to $1.8 million in 2024, then jumped by 409.32% to $9.3 million in 2025.
- According to Business Quant data, Common Equity over the past three periods registered $9.3 million, $8.4 million, and $1.8 million for Q4 2025, Q2 2025, and Q4 2024 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Common Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - | 21.93 Bn |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn | 8.23 Bn |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn | 3.23 Bn |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn | 47.38 Bn |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn | 5.90 Bn |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - | 56.13 Bn |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn | 14.66 Bn |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn | 3.41 Bn |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn | 6.50 Bn |
| 10 | PRF Technologies | 745,168.93 | 451,168.93 | - | 9.29 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 9.29 Mn |
| Jun 30, 2025 | 8.44 Mn |
| Dec 31, 2024 | 1.82 Mn |
| Jun 30, 2024 | -2.04 Mn |
| Mar 31, 2024 | 1.85 Mn |
| Dec 31, 2023 | 7.24 Mn |
| Sep 30, 2023 | 8.64 Mn |
| Jun 30, 2023 | 6.97 Mn |
| Mar 31, 2023 | 8.89 Mn |
| Dec 31, 2022 | 11.02 Mn |
| Sep 30, 2022 | 13.42 Mn |
| Jun 30, 2022 | 15.20 Mn |
| Mar 31, 2022 | 16.70 Mn |
| Dec 31, 2021 | 18.08 Mn |
| Sep 30, 2021 | 19.48 Mn |
| Jun 30, 2021 | 19.01 Mn |
| Mar 31, 2021 | 20.40 Mn |
| Dec 31, 2020 | 16.62 Mn |
| Jun 30, 2020 | -14.16 Mn |
| Dec 31, 2019 | -12.24 Mn |